GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (FRA:GHDN) » Definitions » Other Operating Expense

Brainstorm Cell Therapeutics (FRA:GHDN) Other Operating Expense : €-0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Brainstorm Cell Therapeutics Other Operating Expense?

Brainstorm Cell Therapeutics's Other Operating Expense for the three months ended in Mar. 2024 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.00 Mil.

Brainstorm Cell Therapeutics's quarterly Other Operating Expense increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) but then declined from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€0.00 Mil).

Brainstorm Cell Therapeutics's annual Other Operating Expense increased from Dec. 2021 (€-0.00 Mil) to Dec. 2022 (€0.00 Mil) and increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).


Brainstorm Cell Therapeutics Other Operating Expense Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Other Operating Expense Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Brainstorm Cell Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Brainstorm Cell Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Brainstorm Cell Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Brainstorm Cell Therapeutics (FRA:GHDN) Business Description

Traded in Other Exchanges
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics (FRA:GHDN) Headlines

No Headlines